46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes mellitus (T2DM), reduced glycosylated hemoglobin (HbA(1c)) and weight in 30-week placebo-controlled trials. Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience.

          Related collections

          Author and article information

          Journal
          Clin Ther
          Clinical therapeutics
          Elsevier BV
          0149-2918
          0149-2918
          Jan 2007
          : 29
          : 1
          Affiliations
          [1 ] Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
          Article
          S0149-2918(07)00029-X
          10.1016/j.clinthera.2007.01.015
          17379054
          1694ee56-b794-412b-a3b3-3cda1c6a35c5
          History

          Comments

          Comment on this article